JP2022547298A5 - - Google Patents
Info
- Publication number
- JP2022547298A5 JP2022547298A5 JP2022515475A JP2022515475A JP2022547298A5 JP 2022547298 A5 JP2022547298 A5 JP 2022547298A5 JP 2022515475 A JP2022515475 A JP 2022515475A JP 2022515475 A JP2022515475 A JP 2022515475A JP 2022547298 A5 JP2022547298 A5 JP 2022547298A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- composition
- kit
- hcmv
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897603P | 2019-09-09 | 2019-09-09 | |
| US62/897,603 | 2019-09-09 | ||
| PCT/EP2020/075002 WO2021048081A1 (en) | 2019-09-09 | 2020-09-08 | Immunotherapeutic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547298A JP2022547298A (ja) | 2022-11-11 |
| JP2022547298A5 true JP2022547298A5 (enExample) | 2023-09-15 |
Family
ID=72603444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515475A Pending JP2022547298A (ja) | 2019-09-09 | 2020-09-08 | 免疫療法組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210069321A1 (enExample) |
| EP (1) | EP4028051A1 (enExample) |
| JP (1) | JP2022547298A (enExample) |
| CN (1) | CN114466659A (enExample) |
| BR (1) | BR112022004228A2 (enExample) |
| CA (1) | CA3092525A1 (enExample) |
| IL (1) | IL290854A (enExample) |
| MX (1) | MX2022002823A (enExample) |
| WO (1) | WO2021048081A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019025104A2 (pt) | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição |
| EP3886901A1 (en) * | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| KR20220038608A (ko) * | 2019-05-31 | 2022-03-29 | 배리에이션 바이오테크놀로지스 아이엔씨. | 다형성 교모세포종의 치료를 위한 면역치료 조성물 |
| WO2021038508A1 (en) | 2019-08-30 | 2021-03-04 | Glaxosmithkline Biologicals Sa | Jet mixing lipid nanoparticle manufacturing process |
| WO2023020994A1 (en) * | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| US20260224692A1 (en) * | 2023-01-26 | 2026-08-06 | The General Hospital Corporation | T cell-directed anti-aging and anti-cancer vaccines against commensal cytomegalovirus |
| WO2025179112A1 (en) * | 2024-02-23 | 2025-08-28 | Curevo, Inc. | Immunogenic compositions for the prevention of herpes zoster |
| WO2025180443A1 (en) * | 2024-02-29 | 2025-09-04 | Immunadd Inc. | Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| WO1988009797A1 (en) | 1987-06-05 | 1988-12-15 | The United States Of America, As Represented By Th | Autocrine motility factors in cancer diagnosis and management |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| CA2252972C (en) | 1998-11-26 | 2012-09-18 | National Research Council Of Canada | Serum-free production of recombinant proteins and adenoviral vectors |
| US6210922B1 (en) | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
| PT1284740E (pt) | 2000-05-19 | 2008-07-09 | Corixa Corp | Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos |
| CA2417806C (en) | 2000-08-04 | 2011-05-10 | Corixa Corporation | New immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| CN103550764A (zh) * | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
| CA2728739C (en) * | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| SG190937A1 (en) | 2010-12-14 | 2013-07-31 | Glaxosmithkline Biolog Sa | Mycobacterium antigenic composition |
| JP6232544B2 (ja) * | 2011-11-11 | 2017-11-22 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | サイトメガロウイルスの治療のための組成物及び方法 |
| CN110088227B (zh) | 2016-12-23 | 2023-01-10 | 库斯图姆多特公司 | 具有iii-v族核心和合金化ii-vi族外壳的量子点 |
-
2020
- 2020-09-08 CN CN202080062933.7A patent/CN114466659A/zh active Pending
- 2020-09-08 MX MX2022002823A patent/MX2022002823A/es unknown
- 2020-09-08 JP JP2022515475A patent/JP2022547298A/ja active Pending
- 2020-09-08 EP EP20775584.4A patent/EP4028051A1/en not_active Withdrawn
- 2020-09-08 BR BR112022004228A patent/BR112022004228A2/pt not_active IP Right Cessation
- 2020-09-08 US US17/014,028 patent/US20210069321A1/en not_active Abandoned
- 2020-09-08 WO PCT/EP2020/075002 patent/WO2021048081A1/en not_active Ceased
- 2020-09-08 CA CA3092525A patent/CA3092525A1/en active Pending
-
2022
- 2022-02-23 IL IL290854A patent/IL290854A/en unknown
- 2022-09-08 US US17/940,117 patent/US20230022956A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7785817B2 (ja) | がんに対する組合せ療法 | |
| Chikh et al. | Liposomal delivery of CTL epitopes to dendritic cells | |
| Si et al. | The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up | |
| Gerard et al. | Therapeutic potential of protein and adjuvant vaccinations on tumour growth | |
| KR102351555B1 (ko) | Hpv 및 관련 질환용 면역 증강 치료 백신 | |
| EP2155780B1 (en) | P53 peptide vaccine | |
| EP1925317A1 (de) | Stabilisierte mRNA Tumorvakzine | |
| WO2021228106A1 (zh) | 溶瘤病毒与免疫检查点抑制剂联合治疗肿瘤 | |
| JP2002508333A (ja) | ワクチン | |
| US9974844B2 (en) | Cancer vaccine compositions and methods of using the same | |
| JP2014506562A5 (ja) | 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用 | |
| Yang et al. | Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo | |
| WO2002039951A2 (en) | Yeast-dentritic cell vaccines and uses thereof | |
| Wang et al. | Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly (Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice: Y. Wang et al.: Immune Responses of A VZV-gE Subunit Vaccine | |
| Song et al. | A potential herbal adjuvant combined with a peptide-based vaccine acts against HPV-related tumors through enhancing effector and memory T-cell immune responses | |
| Chang et al. | Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes | |
| KR101361769B1 (ko) | Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신 | |
| JP2001516727A (ja) | 新生物または癌性増殖の治療用もしくは造血の修復または作用促進用の相乗組成物および方法 | |
| JP2021506767A (ja) | Ｂ型肝炎免疫化レジメン及び組成物 | |
| EP4028051A1 (en) | Immunotherapeutic compositions | |
| JP2018500322A5 (enExample) | ||
| JP2017531669A (ja) | Ｐｅｇ化リン脂質を担体とするポリペプチドワクチンミセル | |
| CN119770632A (zh) | 诱导免疫应答的组合物和方法 | |
| Torréns et al. | Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors | |
| KR102728174B1 (ko) | 백신 보조제로서 gm3 강글리오시드의 합성 변이체를 포함하는 나노입자 |